Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces June 2022 inducement grants: the stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Presents Clinical and Research Results at ENDO 2022


Crinetics Pharmaceuticals to present findings from Phase 1 programs of CRN04894 and CRN04777 as well as discovery of PTHR1 antagonist at ENDO 2022.

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference


Crinetics Pharmaceuticals management to participate in a fireside chat at the 2022 JMP Securities Life Sciences Conference

Crinetics Reports Top-line CRN04894 MAD Results from Phase 1 Study


Crinetics Reports Top-Line Phase 1 MAD results showing CRN04894 suppresses cortisol even in presence of disease-like ACTH concentrations

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update


Crinetics reported financial results for the first quarter 2022 and outlined recent progress, including Phase 1 readout from CRN04777, licensing agreement with SKK, and strengthened management team and balance sheet.